Elad Sharon

19.1k total citations · 2 hit papers
270 papers, 8.2k citations indexed

About

Elad Sharon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Elad Sharon has authored 270 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 175 papers in Oncology, 94 papers in Pulmonary and Respiratory Medicine and 35 papers in Hematology. Recurrent topics in Elad Sharon's work include Cancer Immunotherapy and Biomarkers (84 papers), Oral health in cancer treatment (40 papers) and Cancer Diagnosis and Treatment (39 papers). Elad Sharon is often cited by papers focused on Cancer Immunotherapy and Biomarkers (84 papers), Oral health in cancer treatment (40 papers) and Cancer Diagnosis and Treatment (39 papers). Elad Sharon collaborates with scholars based in United States, Israel and Australia. Elad Sharon's co-authors include Rajesh V. Lalla, Joanne M. Bowen, Helen X. Chen, Joel B. Epstein, Stephen T. Sonis, Raffit Hassan, Judith E. Raber‐Durlacher, Noam Yarom, Ourania Nicolatou‐Galitis and César A. Migliorati and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Elad Sharon

253 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

2014 768 citations Elad Sharon et al. profile →
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia

2021 207 citations Patrick A. Brown, Lingyun Ji et al. profile →

Peers

Countries citing papers authored by Elad Sharon

Since Specialization

Citations

This map shows the geographic impact of Elad Sharon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elad Sharon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elad Sharon more than expected).

Fields of papers citing papers by Elad Sharon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elad Sharon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elad Sharon. The network helps show where Elad Sharon may publish in the future.

Co-authorship network of co-authors of Elad Sharon

This figure shows the co-authorship network connecting the top 25 collaborators of Elad Sharon. A scholar is included among the top collaborators of Elad Sharon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elad Sharon. Elad Sharon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort 2025 ·Cancer Communications ·Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Raid Aljumaily, (unknown), (unknown), Sajeve Thomas, William R. Robinson, Hye Sung Kim, (unknown), Christine M. McLeod, Helen X Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock	0
2	Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma 2025 ·npj Precision Oncology ·Sandip Pravin Patel, (unknown), Young Kwang Chae, Shiruyeh Schokrpur, Christopher D. Lao, Benjamin Powers, Adrienne I. Victor, Adedayo A. Onitilo, (unknown), Naoko Takebe, (unknown), Christine M. McLeod, (unknown), Elad Sharon, Megan Othus, (unknown), Charles D. Blanke, Razelle Kurzrock	1
3	Immune checkpoint inhibitors and pregnancy: Considerations for treating medically complex patients with the best available therapy 2025 ·Seminars in Perinatology ·Elad Sharon	1
4	A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183). 2024 ·Journal of Clinical Oncology ·Maha Hussain, Masha Kocherginsky, Parminder Singh, (unknown), Zin Myint, Di Jiang, Elizabeth Wulff‐Burchfield, (unknown), Elad Sharon, Richard Piekarz, Joshua J. Meeks, David James VanderWeele	2
5	A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer. 2024 ·Journal of Clinical Oncology ·Thatcher Heumann, Mark Yarchoan, (unknown), Jiayun Lu, Daneng Li, Paul R. Kunk, Renuka Iyer, Farshid Dayyani, Lionel Aurelien Kankeu Fonkoua, (unknown), Olumide B. Gbolahan, Milind Javle, S. Lindsey Davis, Vaia Florou, James R. Wright, Elad Sharon, Hao Wang, Gregory B. Lesinski, Nilofer S. Azad	3
6	2367P A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC) 2023 ·Annals of Oncology ·Russell K. Pachynski, Gurkamal Chatta, Rohit Jain, Helen Moon, Randy F. Sweis, (unknown), Fang Tian, Steven P. Fling, André Lacroix, Judith C. Kaiser, Elad Sharon, Evan Y. Yu	1
7	The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990–2018 2023 ·Cancer Epidemiology Biomarkers & Prevention ·Nadia Howlader, Elad Sharon, (unknown), Lori A. Ehrlich, Nicholas C. Richardson, Nicole Gormley, R. Angelo de Claro, (unknown), Angela B. Mariotto, Kathleen A. Cronin	5
8	1979P phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS) 2023 ·Annals of Oncology ·Kathryn Lurain, Ramya Ramaswami, Irene Ekwede, (unknown), Gaurav Goyal, Manoj Menon, Thomas Odeny, Elad Sharon, Michael J. Wagner, Chi‐Chuan Wang, Nina Bhardwaj, Maher Abdul‐Hay, Judith C. Kaiser, Alan F. Wright, Robert Yarchoan, Steven P. Fling, Qiang Lü, Thomas S. Uldrick	2
9	Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse 2023 ·Journal of Clinical Oncology ·Laura Hogan, Patrick A. Brown, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, Teena Bhatla, Michael J. Borowitz, Elizabeth A. Raetz, Andrew J. Carroll, Nyla A. Heerema, Gerhard Zugmaier, Elad Sharon, M. Brooke Bernhardt, Stephanie Terezakis, Lia Gore, James A. Whitlock, Stephen P. Hunger, Mignon L. Loh	33
10	Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development 2023 ·Journal for ImmunoTherapy of Cancer ·Hussein A. Tawbi, Ryan J. Sullivan, David Feltquate, Theresa LaVallee, Naiyer A. Rizvi, Elad Sharon, Jeffrey A. Sosman, Harriet M. Kluger	7
11	The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapies 2023 ·JNCI Journal of the National Cancer Institute ·Ananth Annapragada, Andrew G. Sikora, Himangi Marathe, (unknown), Michael Demetriou, Lawrence Fong, Jinming Gao, Donald Küfe, Zachary S. Morris, Eduardo Vilar, Elad Sharon, Alan D. Hutson, Kunle Odunsi	2
12	Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer 2022 ·Clinical Cancer Research ·(unknown), Mark Yarchoan, Subir Goyal, Yuan Liu, Elad Sharon, (unknown), Brian M. Olson, Chrystal M. Paulos, Bassel F. El‐Rayes, Shishir K. Maithel, Nilofer S. Azad, Gregory B. Lesinski	10
13	Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program 2022 ·Journal of Clinical Oncology ·Abdul Rafeh Naqash, Melissa Moey, (unknown), (unknown), (unknown), Nagabhishek Moka, Shanda Finnigan, James H. Murray, Douglas B. Johnson, Javid J. Moslehi, Elad Sharon	48
14	A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations) 2021 ·Blood ·Anjali S. Advani, Anna Moseley, Kristen M. O’Dwyer, Brent L. Wood, Jae H. Park, Matthew J. Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab Atallah, Aaron T. Gerds, Susan O’Brien, Jane L. Liesveld, Megan Othus, Mark R. Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba	9
15	Ocular adverse events in PD-1 and PD-L1 inhibitors 2021 ·SHILAP Revista de lepidopterología ·James H. Murray, Howard Streicher, Elad Sharon, (unknown), Shanda Finnigan, H. Nida Sen, Helen X Chen	25
16	Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute 2021 ·The Oncologist ·Arjun Mittra, Abdul Rafeh Naqash, James H. Murray, Shanda Finnigan, Joanne Kwak‐Kim, S. Percy Ivy, Alice P. Chen, Elad Sharon	20
17	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331 2019 ·Blood ·Patrick A. Brown, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, Laura Hogan, Michael J. Borowitz, Elizabeth A. Raetz, Gerhard Zugmaier, Elad Sharon, Lia Gore, James A. Whitlock, Michael A. Pulsipher, Stephen P. Hunger, Mignon L. Loh	51
18	Tuberculosis following PD-1 blockade for cancer immunotherapy 2019 ·Science Translational Medicine ·Daniel L. Barber, Shunsuke Sakai, Ragini R. Kudchadkar, Steven P. Fling, Tracey A. Day, Julie Vergara, David Ashkin, (unknown), Lisa Lundgren, Vanessa Raabe, Colleen S. Kraft, Jorge J. Nieva, Martin A. Cheever, Paul Nghiem, Elad Sharon	132
19	[Antibiotic prophylaxis for the prevention of infective endocarditis--new guidelines of the American Heart Association]. 2007 ·PubMed ·Elad Sharon, (unknown), Rafael Benoliel	1
20	Possible Association between Diabetes and Bisphosphonate-Related Jaw Osteonecrosis 2006 ·The Journal of Clinical Endocrinology & Metabolism ·Mogher Khamaisi, Eran Regev, Noam Yarom, Batia Avni, Eran Leitersdorf, Itamar Raz, Elad Sharon	140

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact